414 related articles for article (PubMed ID: 33503955)
1. A Novel Salt Inducible Kinase 2 Inhibitor, ARN-3261, Sensitizes Ovarian Cancer Cell Lines and Xenografts to Carboplatin.
Fan D; Yang H; Mao W; Rask PJ; Pang L; Xu C; Vankayalapat H; Ahmed AA; Bast RC; Lu Z
Cancers (Basel); 2021 Jan; 13(3):. PubMed ID: 33503955
[TBL] [Abstract][Full Text] [Related]
2. A Novel Compound ARN-3236 Inhibits Salt-Inducible Kinase 2 and Sensitizes Ovarian Cancer Cell Lines and Xenografts to Paclitaxel.
Zhou J; Alfraidi A; Zhang S; Santiago-O'Farrill JM; Yerramreddy Reddy VK; Alsaadi A; Ahmed AA; Yang H; Liu J; Mao W; Wang Y; Takemori H; Vankayalapati H; Lu Z; Bast RC
Clin Cancer Res; 2017 Apr; 23(8):1945-1954. PubMed ID: 27678456
[No Abstract] [Full Text] [Related]
3. The Small-Molecule Inhibitor MRIA9 Reveals Novel Insights into the Cell Cycle Roles of SIK2 in Ovarian Cancer Cells.
Raab M; Rak M; Tesch R; Gasimli K; Becker S; Knapp S; Strebhardt K; Sanhaji M
Cancers (Basel); 2021 Jul; 13(15):. PubMed ID: 34359562
[TBL] [Abstract][Full Text] [Related]
4. SIK2 is a centrosome kinase required for bipolar mitotic spindle formation that provides a potential target for therapy in ovarian cancer.
Ahmed AA; Lu Z; Jennings NB; Etemadmoghadam D; Capalbo L; Jacamo RO; Barbosa-Morais N; Le XF; ; Vivas-Mejia P; Lopez-Berestein G; Grandjean G; Bartholomeusz G; Liao W; Andreeff M; Bowtell D; Glover DM; Sood AK; Bast RC
Cancer Cell; 2010 Aug; 18(2):109-21. PubMed ID: 20708153
[TBL] [Abstract][Full Text] [Related]
5. Salt-inducible kinase 2 regulates mitotic progression and transcription in prostate cancer.
Bon H; Wadhwa K; Schreiner A; Osborne M; Carroll T; Ramos-Montoya A; Ross-Adams H; Visser M; Hoffmann R; Ahmed AA; Neal DE; Mills IG
Mol Cancer Res; 2015 Apr; 13(4):620-635. PubMed ID: 25548099
[TBL] [Abstract][Full Text] [Related]
6. The Bcl-2/Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin.
Witham J; Valenti MR; De-Haven-Brandon AK; Vidot S; Eccles SA; Kaye SB; Richardson A
Clin Cancer Res; 2007 Dec; 13(23):7191-8. PubMed ID: 18056200
[TBL] [Abstract][Full Text] [Related]
7. The insulin-like growth factor-I receptor kinase inhibitor, NVP-ADW742, sensitizes small cell lung cancer cell lines to the effects of chemotherapy.
Warshamana-Greene GS; Litz J; Buchdunger E; García-Echeverría C; Hofmann F; Krystal GW
Clin Cancer Res; 2005 Feb; 11(4):1563-71. PubMed ID: 15746061
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of miR-203 sensitizes paclitaxel (Taxol)-resistant colorectal cancer cells through targeting the salt-inducible kinase 2 (SIK2).
Liu Y; Gao S; Chen X; Liu M; Mao C; Fang X
Tumour Biol; 2016 Sep; 37(9):12231-12239. PubMed ID: 27236538
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of phosphatidylinositol 3-kinase sensitizes ovarian cancer cells to carboplatin and allows adjunct chemotherapy treatment.
Westfall SD; Skinner MK
Mol Cancer Ther; 2005 Nov; 4(11):1764-71. PubMed ID: 16275998
[TBL] [Abstract][Full Text] [Related]
10. SIK2 promotes reprogramming of glucose metabolism through PI3K/AKT/HIF-1α pathway and Drp1-mediated mitochondrial fission in ovarian cancer.
Gao T; Zhang X; Zhao J; Zhou F; Wang Y; Zhao Z; Xing J; Chen B; Li J; Liu S
Cancer Lett; 2020 Jan; 469():89-101. PubMed ID: 31639424
[TBL] [Abstract][Full Text] [Related]
11. Influence of a novel histone deacetylase inhibitor panobinostat (LBH589) on the growth of ovarian cancer.
Garrett LA; Growdon WB; Rueda BR; Foster R
J Ovarian Res; 2016 Sep; 9(1):58. PubMed ID: 27633667
[TBL] [Abstract][Full Text] [Related]
12. The HDACi Panobinostat Shows Growth Inhibition Both In Vitro and in a Bioluminescent Orthotopic Surgical Xenograft Model of Ovarian Cancer.
Helland Ø; Popa M; Bischof K; Gjertsen BT; McCormack E; Bjørge L
PLoS One; 2016; 11(6):e0158208. PubMed ID: 27352023
[TBL] [Abstract][Full Text] [Related]
13. Salt-Inducible Kinase 2-Triggered Release of Its Inhibitor from Hydrogel to Suppress Ovarian Cancer Metastasis.
Hua Y; Yin H; Liu X; Xie J; Zhan W; Liang G; Shen Y
Adv Sci (Weinh); 2022 Aug; 9(22):e2202260. PubMed ID: 35618488
[TBL] [Abstract][Full Text] [Related]
14. Long non-coding RNA UCA1 promotes the progression of paclitaxel resistance in ovarian cancer by regulating the miR-654-5p/SIK2 axis.
Li ZY; Wang XL; Dang Y; Zhu XZ; Zhang YH; Cai BX; Zheng L
Eur Rev Med Pharmacol Sci; 2020 Jan; 24(2):591-603. PubMed ID: 32016960
[TBL] [Abstract][Full Text] [Related]
15. SIK2 promotes ovarian cancer cell motility and metastasis by phosphorylating MYLK.
Shi X; Yu X; Wang J; Bian S; Li Q; Fu F; Zou X; Zhang L; Bast RC; Lu Z; Guo L; Chen Y; Zhou J
Mol Oncol; 2022 Jul; 16(13):2558-2574. PubMed ID: 35278271
[TBL] [Abstract][Full Text] [Related]
16. [Alteration of survivin gene expression in ovarian cancer cell line CAOV3 after chemotherapy in vitro].
Zhang SL; Jiang T; Lin B; Zhao CQ; Meng LR
Zhonghua Fu Chan Ke Za Zhi; 2004 Jul; 39(7):482-5. PubMed ID: 15347474
[TBL] [Abstract][Full Text] [Related]
17. [Effects of hyperthermia combined platinum-based drugs on ovarian cancer cell lines SKOV3].
Xie D; Yin RT; Li KM; Xiao P; Tong LX
Sichuan Da Xue Xue Bao Yi Xue Ban; 2014 Jul; 45(4):606-11. PubMed ID: 25286685
[TBL] [Abstract][Full Text] [Related]
18. The Selective SIK2 Inhibitor ARN-3236 Produces Strong Antidepressant-Like Efficacy in Mice via the Hippocampal CRTC1-CREB-BDNF Pathway.
Liu Y; Tang W; Ji C; Gu J; Chen Y; Huang J; Zhao X; Sun Y; Wang C; Guan W; Liu J; Jiang B
Front Pharmacol; 2020; 11():624429. PubMed ID: 33519490
[TBL] [Abstract][Full Text] [Related]
19. S100A10 silencing suppresses proliferation, migration and invasion of ovarian cancer cells and enhances sensitivity to carboplatin.
Wang L; Yan W; Li X; Liu Z; Tian T; Chen T; Zou L; Cui Z
J Ovarian Res; 2019 Nov; 12(1):113. PubMed ID: 31739800
[TBL] [Abstract][Full Text] [Related]
20. Neurotensin Receptor 1 Antagonist SR48692 Improves Response to Carboplatin by Enhancing Apoptosis and Inhibiting Drug Efflux in Ovarian Cancer.
Liu J; Agopiantz M; Poupon J; Wu Z; Just PA; Borghese B; Ségal-Bendirdjian E; Gauchotte G; Gompel A; Forgez P
Clin Cancer Res; 2017 Nov; 23(21):6516-6528. PubMed ID: 28790113
[No Abstract] [Full Text] [Related]
[Next] [New Search]